Literature DB >> 6438857

Intravesical and systemic chemotherapy in the management of superficial bladder cancer.

M S Soloway.   

Abstract

Before deciding to begin intravesical prophylaxis, the physician must categorize the patient with respect to the stage of the tumor and the multiplicity of lesions. This may require mucosal biopsies in order to determine whether the patient had unifocal or multifocal disease. Thiotepa, mitomycin C, and doxorubicin hydrochloride are discussed specifically and compared.

Entities:  

Mesh：

Substances：

Year:  1984        PMID： 6438857

Source DB:  PubMed          Journal:  Urol Clin North Am        ISSN： 0094-0143            Impact factor:   2.241


  6 in total

1.  Clinical significance of nuclear p53 protein accumulation in bladder cancer.

Authors:  G Toktaş; L N Türkeri; E Unlüer; M Calişkan; B Aksoy; A Akdaş
Journal:  Int Urol Nephrol       Date:  1999       Impact factor: 2.370

2.  Intravesical administration of tumor-associated monoclonal antibody AUA1 in transitional cell carcinoma of the bladder: a study of biodistribution.

Authors:  J Zorzos; D V Skarlos; A A Epenetos; D Pectasides; P Koutsioumba; J Elemenoglou; A Bakiras; M Likourinas; K Dimopoulos
Journal:  Urol Res       Date:  1993

3.  A phase II study of prophylactic intravesical chemotherapy with epirubicin in the treatment of superficial bladder cancer. Tokyo Women's Medical College Bladder Cancer Collaborating Group.

Authors:  O Ryoji; H Toma; H Nakazawa; N Goya; T Okumura; T Sonoda; T Kihara; K Tanabe; S Onizuka; H Tomoe
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

4.  Inhibition of bladder tumor cell implantation in cauterized urothelium, without inhibition of healing, by a fibronectin-related peptide (GRGDS).

Authors:  L M Hyacinthe; T W Jarrett; C S Gordon; E D Vaughan; G F Whalen
Journal:  Ann Surg Oncol       Date:  1995-09       Impact factor: 5.344

5.  Treatment of bladder carcinoma in situ with mitomycin C: long-term follow-up.

Authors:  R Minervini; R Felipetto; L Viganò; M Cecchi
Journal:  Int Urol Nephrol       Date:  1994       Impact factor: 2.370

6.  Selection of patients for intravesical therapy for superficial bladder cancer.

Authors:  Y Bedük; L S Yaman; S Baltaci; Y Z Müftüoğlu; T Yurdakul; O Göğüş
Journal:  Int Urol Nephrol       Date:  1994       Impact factor: 2.370
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.